Evidence map›Paper›PMID 27311730›Full record

Trial reportJournal of neuro-oncology2016

A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma.

Kent C Shih, Sajeel Chowdhary, Paul Rosenblatt, Alva B Weir, Gregg C Shepard, Jeffrey T Williams, Mythili Shastry, Howard A Burris, John D Hainsworth

Registry-linked trialAbstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Journal of neuro-oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05425004 (A Phase II Study of Cabozantinib for Patients With Recurrent or Progressive Meningioma), which is not on this map. Cited by 78 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed, 5 pooled it
5.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05425004 phase2recruitingnot on this mapstarted 2022, after this paper: background citation

A Phase II Study of Cabozantinib for Patients With Recurrent or Progressive Meningioma

TypeinterventionalSponsorBaptist Health South FloridaRan2022 to 2028Enrolled24ConditionsMeningiomaArmsCabozantinib
3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 5 syntheses or guidelines pooled it, 123 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Kent C ShihSarah Cannon Research Institute, 250 25th Avenue North, Suite 200, Nashville, TN, 37203, USA. kshih@tnonc.com.
Sajeel ChowdharyFlorida Hospital Cancer Institute, Orlando, FL, USA.
Paul RosenblattSarah Cannon Research Institute, 250 25th Avenue North, Suite 200, Nashville, TN, 37203, USA.
Alva B WeirWest Clinic, Memphis, TN, USA.
Gregg C ShepardSarah Cannon Research Institute, 250 25th Avenue North, Suite 200, Nashville, TN, 37203, USA.
Jeffrey T WilliamsSaint Thomas Hospital, Nashville, TN, USA.
Mythili ShastrySarah Cannon Research Institute, 250 25th Avenue North, Suite 200, Nashville, TN, 37203, USA.
Howard A BurrisSarah Cannon Research Institute, 250 25th Avenue North, Suite 200, Nashville, TN, 37203, USA.
John D HainsworthSarah Cannon Research Institute, 250 25th Avenue North, Suite 200, Nashville, TN, 37203, USA.
Sarah Cannon · USCampbell Clinic · USFlorida Hospital Cancer Institute · USSaint Thomas West Hospital · USTennessee Oncology · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Meningiomas that progress after standard therapies are challenging with limited effective chemotherapy options. This phase II trial evaluated the efficacy of everolimus plus bevacizumab in patients with recurrent, progressive meningioma after treatment with surgical resection and local radiotherapy when appropriate. Patients with recurrent meningioma (WHO grade I, II, or III) following standard treatments with surgical resection and radiotherapy received bevacizumab (10 mg/kg IV days 1 and 15) and everolimus (10 mg PO daily) each 28 day cycle. Evaluation of response occurred every 2 cycles. The primary endpoint was progression-free survival (PFS). Secondary endpoints included response rate, overall survival and safety. Seventeen patients with a median age of 59 years (29-84) received study treatment. WHO grades at study entry included: I, 5 (29 %); II, 7 (41 %); III, 4 (24 %); unknown, 1 (6 %). Patients received a median of 8 cycles (1-37); all patients are off study treatment. A best response of SD was observed in 15 patients (88 %), and 6 patients had SD for >12 months. Overall median PFS was 22 months (95 % CI 4.5-26.8) and was greater for patients with WHO grade II and III compared to grade I tumors (22.0 months vs 17.5 months). Four patients discontinued treatment due to toxicity (proteinuria, 2; colitis, 1, thrombocytopenia, 1). However, other grade 3 toxicity was uncommon, and no patient had grade 4 toxicity. The combination of everolimus and bevacizumab was well-tolerated, and produced stable disease in 88 % of patients; the median duration of disease stabilization of 10 months (2-29). The median PFS from this prospective trial was similar to previous retrospective reports of bevacizumab in the treatment of recurrent meningioma.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Agents, ImmunologicalBevacizumabBrain NeoplasmsDisease-Free SurvivalEverolimusFemaleHumansImmunosuppressive AgentsInjections, IntravenousMagnetic Resonance ImagingMaleMeningiomaMiddle AgedAntineoplastic Agents, ImmunologicalBevacizumabEverolimusImmunosuppressive AgentsBevacizumabEverolimusMeningioma

Identifiers

PMID27311730
OpenAlexW2426305918

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.